A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits totaling more than $2 billion circulated online in August 2025.  Claims of lawsuits against Ozempic and similar drugs are indeed true.

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, jumped 5% through 9:55 a.m. ET Monday on a series of positive announcements for its GLP-1 products.

Data to highlight the impact of Wegovy® (semaglutide 2.4 mg) on atrial fibrillation – a common heart rhythm condition – in people living with obesity (SELECT study)Additional Rybelsus® and Ozempic® da

Multiple lawsuits have been filed against the makers of the popular weight-loss drug. Litigants cite blindness and other side-effects.

Discover potential risks for Novo Nordisk using Charlie Munger's inversion model. Explore market share, R&D, and why this stock may double in 5 years.

Over 1,800 lawsuits claim Ozempic caused stomach paralysis, vision loss, and more. Read what’s next in the legal fight.